Zacks Research Has Negative Outlook for Novartis Q1 Earnings

Novartis AG (NYSE:NVS) – Equities research analysts at Zacks Research dropped their Q1 2026 earnings estimates for Novartis in a report issued on Wednesday, January 15th. Zacks Research analyst E. Bagri now anticipates that the company will earn $2.07 per share for the quarter, down from their prior estimate of $2.09. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $8.96 EPS.

A number of other research firms have also recently commented on NVS. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets upped their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Down 0.4 %

NYSE NVS opened at $97.51 on Monday. Novartis has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $199.30 billion, a P/E ratio of 11.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. The stock’s 50-day moving average price is $100.61 and its 200-day moving average price is $109.01.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period in the prior year, the business posted $1.74 EPS.

Institutional Trading of Novartis

Hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC bought a new position in Novartis during the second quarter valued at approximately $22,979,000. Brighton Jones LLC boosted its position in shares of Novartis by 10.1% during the 2nd quarter. Brighton Jones LLC now owns 5,399 shares of the company’s stock valued at $575,000 after acquiring an additional 495 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Novartis by 3.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 6,559 shares of the company’s stock valued at $698,000 after purchasing an additional 232 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Novartis in the second quarter worth $64,610,000. Finally, King Luther Capital Management Corp raised its stake in Novartis by 5.0% during the second quarter. King Luther Capital Management Corp now owns 9,523 shares of the company’s stock valued at $1,014,000 after purchasing an additional 456 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.